14.79
-0.06 (-0.40%)
| Penutupan Terdahulu | 14.85 |
| Buka | 14.49 |
| Jumlah Dagangan | 1,100,454 |
| Purata Dagangan (3B) | 1,546,106 |
| Modal Pasaran | 1,949,921,920 |
| Harga / Pendapatan (P/E TTM) | 26.41 |
| Harga / Pendapatan (P/E Ke hadapan) | 19.57 |
| Harga / Jualan (P/S) | 7.91 |
| Harga / Buku (P/B) | 5.35 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2025 |
| Margin Keuntungan | 16.11% |
| Margin Operasi (TTM) | 37.43% |
| EPS Cair (TTM) | 0.270 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 24.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 22.25% |
| Nisbah Semasa (MRQ) | 5.93 |
| Aliran Tunai Operasi (OCF TTM) | 64.29 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 47.49 M |
| Pulangan Atas Aset (ROA TTM) | 5.20% |
| Pulangan Atas Ekuiti (ROE TTM) | 11.23% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Aurinia Pharmaceuticals Inc | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.88 |
|
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 9.07% |
| % Dimiliki oleh Institusi | 47.53% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 21.00 (Jefferies, 41.99%) | Beli |
| Median | 16.00 (8.18%) | |
| Rendah | 15.00 (RBC Capital, 1.42%) | Pegang |
| Purata | 17.33 (17.17%) | |
| Jumlah | 1 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 14.66 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Leerink Partners | 03 Dec 2025 | 16.00 (8.18%) | Pegang | 14.91 |
| Jefferies | 07 Nov 2025 | 21.00 (41.99%) | Beli | 14.61 |
| RBC Capital | 05 Nov 2025 | 15.00 (1.42%) | Pegang | 14.45 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |